0001104659-21-078158.txt : 20210608 0001104659-21-078158.hdr.sgml : 20210608 20210608142624 ACCESSION NUMBER: 0001104659-21-078158 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210604 FILED AS OF DATE: 20210608 DATE AS OF CHANGE: 20210608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sabba Stephen L CENTRAL INDEX KEY: 0001442372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 211001894 MAIL ADDRESS: STREET 1: DORSET MANAGEMENT CORP STREET 2: 485 UNDERHILL BLVD SUITE 205 CITY: SYOSSET STATE: NY ZIP: 11791 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 tm2119120-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-06-04 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001442372 Sabba Stephen L DORSET MANAGEMENT CORP 485 UNDERHILL BLVD SUITE 205 SYOSSET NY 11791 1 0 0 0 Common Stock 2021-06-04 4 A 0 630 0.00 A 25061 D Non-Qualified Stock Option (right to buy) 115.39 2021-06-04 4 A 0 3269 0 D 2031-06-04 Common Stock 3269 3269 D Non-Qualified Stock Option (right to buy) 117.58 2030-06-10 Common Stock 2468 2468 D These securities, as represented in Column 5, include a grant of 630 restricted shares approved by the Board of Directors of the Company at the 2021 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. These securities, as represented in Column 5, were acquired by a grant of 3,269 shares approved by the Board of Directors of the Company at the 2021 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time. These securities, as represented in Column 5, were acquired by a grant of 2,468 shares approved by the Board of Directors of the Company at the 2020 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 12, 2020. /s/Stephen L. Sabba 2021-06-08